The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Joon Lee - Truist Securities - Analyst
: (technical difficulty) taking questions.
So my first question is, now that FIRDAPSE will be commercially available in Japan this year, what are you looking for in a partner to commercialize
in other regions such as China? And then as a follow-up, just curious what drove the gross to net adjustment for FYCOMPA? And how should we
expect that to trend going forward?
Question: Joon Lee - Truist Securities - Analyst
: Yeah, sorry. I was just curious what drove the gross to net adjustment for FYCOMPA and how we should expect that to trend going forward? Thank
you.
Question: Joon Lee - Truist Securities - Analyst
: Thank you.
Question: Charles Duncan - Cantor Fitzgerald - Analyst
: Hey, good morning, Rich and team. Congrats on a nice quarter and thanks for taking our question. I had questions around AGAMREE versus FIRDAPSE
and commercial strategy. First of all, when you think about FIRDAPSE, it seems like it's about finding new patients. With AGAMREE, it's a little bit
different.
So can you help us understand the synergies that you see in the commercial efforts? And then I had a follow-up on the SUMMIT study.
Question: Charles Duncan - Cantor Fitzgerald - Analyst
: That's helpful. My follow-up question is, I guess that's a great segue to my follow-up, which is on the SUMMIT study. I'm wondering if you could
provide a little bit more color on what you anticipate for that study over the course of the next year in terms of number of patients? And really,
what is the target product profile that you are seeking in terms of the enhanced label with that study?
Question: Charles Duncan - Cantor Fitzgerald - Analyst
: Excellent. Thanks for taking the question and appreciate the guidance raise.
Question: Samantha Semenkow - Citi Investment Research - Analyst
: Hi. Good morning and thanks for taking the question. Just a quick one on AGAMREE. I know it's really early in the launch, but I'm curious if you're
seeing any trends on durability of therapy so far as in are patients tending to stay on therapy after switching?
And then again, your patient mix seems to be quite stable compared to last quarter. Is the expectation that this trend will continue? Or do you
expect it to shift at some point in the future? Thank you.
Question: Samantha Semenkow - Citi Investment Research - Analyst
: Yes, exactly.
Question: Samantha Semenkow - Citi Investment Research - Analyst
: Great. Thank you. And just a follow-up on the discontinuation rate. For that, can you just elaborate on what makes that really positive in your view?
And also what is driving the 15% that you're seeing discontinue? Thank you.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
NOVEMBER 07, 2024 / 1:30PM, CPRX.OQ - Q3 2024 Catalyst Pharmaceuticals Inc Earnings Call
Question: Samantha Semenkow - Citi Investment Research - Analyst
: What are the drivers? Yes, exactly.
Question: Samantha Semenkow - Citi Investment Research - Analyst
: Got it. That's super helpful. Thank you for the question and congrats on the good quarter.
| 
